Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at [email protected] 2018 in Chicago.
Topical cenegermin has been approved by the FDA for the treatment of moderate-to-severe neurotrophic keratitis (NK), ushering in a breakthrough of management.
Retina specialists who use compounded bevacizumab off-label to treat wet age-related macular degeneration are being warned that counterfeit vials of the cancer drug have turned up in oncology practices in the United States.
Analyses of 24-month data from the two pivotal phase III trials investigating a proprietary fluocinolone acetonide-releasing intravitreal insert for the treatment of diabetic macular edema generated positive results that are the basis of filing a new drug application with the FDA.
Concern about potential long-term toxicity associated with use of mitomycin-C is driving researchers to identify new pharmacologic approaches for managing haze formation after PRK.
Results from an interim analysis of a phase II study show fenretinide is well tolerated and exhibits promising biological activity in slowing lesion growth in patients with advanced geographic atrophy associated with age-related macular degeneration.
Preliminary results from a phase 1 safety and tolerability study show no dose-limiting toxicity so far in patients treated with intravitreal injections of volociximab in combination with anti-VEGF therapy for neovascular age-related macular degeneration.
Ranibizumab for the treatment of macular edema associated with central retinal vein occlusion demonstrated rapid and sustained improvement as early as 7 days after the start of treatment through 6-month interim analysis.
Compared with sham injections, monthly injections of 0.3 or 0.5 mg of ranibizumab significantly reduced macular edema and improved best-corrected visual acuity in patients with branch retinal vein occlusion.